CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 40 enrolled
Drug / intervention
Onset Sodium Bicarbonate Inj., 8.4%, USP Neutralizing Additive Solution +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05227300
NCT05227300Phase 4Completed
CompareCT.gov

Buffered vs. Unbuffered Local Anesthesia in Mandibular Molars Diagnosed With Symptomatic Irreversible Pulpitis: A Controlled, Randomized Double-blind Study

Indiana University·interventional·Posted Feb 7, 2022·Updated May 14, 2024

In Brief

A Phase 4 clinical trial evaluating Onset Sodium Bicarbonate Inj., 8.4%, USP Neutralizing Additive Solution and 2% lidocaine with 1:100,000 epinephrine for Symptomatic Irreversible Pulpitis. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether one type of anesthetic (numbing medicine) will work better at numbing the nerve in a tooth than using a different type of anesthetic. A second purpose is to see if the time needed to numb the nerve in a tooth is different between the two anesthetics.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSymptomatic Irreversible Pulpitis
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20222023202420252026
First PostedFeb 7, 2022
Enrollment StartFeb 14, 2022
Primary CompletionMay 23, 2022
Study CompletionJun 30, 2022
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 4.4 years ago

Interventions

Onset Sodium Bicarbonate Inj., 8.4%, USP Neutralizing Additive Solutiondrug

Onpharma's Onset sodium bicarbonate buffer to be added to a standard cartridge of dental local anesthetic

2% lidocaine with 1:100,000 epinephrinedrug

Septodont's standard formulation of 2% lidocaine with epinephrine